CareDx, Inc (CDNA)
After hours:
| Previous Close | 25.15 |
| Open | 25.85 |
| Bid | 21.58 x 1200 |
| Ask | 36.45 x 800 |
| Day's Range | 24.25 - 26.26 |
| 52 Week Range | 21.25 - 96.88 |
| Volume | |
| Avg. Volume | 818,893 |
| Market Cap | 1.376B |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 |
| Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 60.29 |
- GlobeNewswire
CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction
Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant OutcomesSOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gimé
- GlobeNewswire
In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx
Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents that are variations of the o
- GlobeNewswire
CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference
Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant MonitoringSOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will be presenting the latest information on its AlloS
